Details of the Drug Combinations

General Information of This Drug (ID: DMOH8VY)

• Drug Name: Dacomitinib (DMOH8VY)
• Synonyms: PF-00299804

Indication

Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dacomitinib + Idarubicin	DCLWJ1O	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dacomitinib + Osimertinib	DCEN7RW	Osimertinib	EGFR Gene Mutation	[3]
Doxycycline + Dacomitinib	DCH6V8Z	Doxycycline	Non Small Cell Lung Cancer (NSCLC)	[4]
PF-05212384 + Dacomitinib	DC8U0J7	PF-05212384	Neoplasm	[5]
Dacomitinib + Osimertinib	DCBFNEK	Osimertinib	NSCLC	[6]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT03755102) A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
• [4] ClinicalTrials.gov (NCT01465802) Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
• [5] ClinicalTrials.gov (NCT01920061) A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
• [6] ClinicalTrials.gov (NCT04811001) Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations